Literature DB >> 10341706

Insights into cancer from transgenic mouse models.

K F Macleod1, T Jacks.   

Abstract

The generation of mice designed to overexpress activated forms of oncogenes or carrying targeted mutations in tumour suppressor genes, has allowed scientists to causally link the function of these genes with specific tumour processes, such as proliferation, apoptosis, angiogenesis or metastasis. In addition, these mice have been interbred to assess the extent of cooperativity between different genetic lesions in disease progression, leading to a greater understanding of the multi-stage nature of tumourigenesis. The effect of genetic mutations is often influenced by the genetic background of the mouse and by analysing strain-dependent phenotypes, modifier loci have been identified. Although genetic mutations in mouse and humans do not always lead to the same tumour spectrum, the underlying molecular mechanisms are frequently relevant to both species. Furthermore, new technical approaches creating conditional mouse mutants which develop tumours in a tissue-specific manner, will allow the effect of mutation of certain genes to be studied in specific tissues, free from the fatal effects of the mutation in other clinically less relevant tissues. Several exising mouse strains have already been used to develop and test new therapies and conditional mutagenesis will undoubtedly increase the potential use of transgenic mice in understanding and treating cancer.

Entities:  

Mesh:

Year:  1999        PMID: 10341706     DOI: 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

1.  Transgenic expression of walleye dermal sarcoma virus rv-cyclin (orfA) in zebrafish does not result in tissue proliferation.

Authors:  Thomas A Paul; Joel Rovnak; Sandra L Quackenbush; Kathleen Whitlock; Huiqing Zhan; Zhiyuan Gong; Jan Spitsbergen; Paul R Bowser; James W Casey
Journal:  Mar Biotechnol (NY)       Date:  2010-03-28       Impact factor: 3.619

Review 2.  Animal models of cell cycle dysregulation and the pathogenesis of gliomas.

Authors:  E C Holland
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

3.  A cascade of modules of a network defines cancer progression.

Authors:  Sam Thiagalingam
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 4.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

5.  Of mice and men: the evolution of animal welfare guidelines for cancer research.

Authors:  N Dey; P De; B R Smith; B Leyland-Jones
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

Review 6.  Rebuilding cancer metastasis in the mouse.

Authors:  Meera Saxena; Gerhard Christofori
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

7.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 8.  The use of genetically modified mice in cancer risk assessment: challenges and limitations.

Authors:  David A Eastmond; Suryanarayana V Vulimiri; John E French; Babasaheb Sonawane
Journal:  Crit Rev Toxicol       Date:  2013-09       Impact factor: 5.635

9.  Strain background alters mammary gland lesion phenotype in transforming growth factor-alpha transgenic mice.

Authors:  Teresa A Rose-Hellekant; Kennedy Gilchrist; Eric P Sandgren
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

Review 10.  Experimental models of hepatocellular carcinoma.

Authors:  Philippa Newell; Augusto Villanueva; Scott L Friedman; Kazuhiko Koike; Josep M Llovet
Journal:  J Hepatol       Date:  2008-01-30       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.